← back to search

Dan Turner

Hebrew University of Jerusalem · IL
Area of research
Genetics · Epidemiology
Research interest
Research focused on Ulcerative colitis and Inflammatory bowel disease, with related work in Ustekinumab, Interquartile range, Incidence (geometry). Notable publications include 'Global evolution of inflammatory bowel disease across epidemiologic stages', 'Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases', and 'Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN'.
h-index
citations
577
works
26
NIH funding
primary concept
email

Recent publications

Global evolution of inflammatory bowel disease across epidemiologic stages
Nature 2025cited by 259position: middledoi
Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
Alimentary Pharmacology & Therapeutics 2025cited by 18position: middledoi
Management of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation
Journal of Pediatric Gastroenterology and Nutrition 2025cited by 14position: middledoi
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
Journal of Pediatric Gastroenterology and Nutrition 2025cited by 10position: middledoi
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the <scp>VedoKids</scp> Prospective Multicentre Study
Alimentary Pharmacology & Therapeutics 2025cited by 7position: middledoi
Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials
Gut 2025cited by 4position: firstdoi
P1059 Fecal calprotectin response to Tasty&amp;Healthy dietary intervention in asymptomatic children and young adults with biologically active Crohn’s disease: results of the “TASTI-E” randomized controlled trial
Journal of Crohn s and Colitis 2025cited by 2position: lastdoi
P0557 Multiomics analysis identifies key pathways associated with severe disease course in children with IBD: a prospective study
Journal of Crohn s and Colitis 2025cited by 1position: lastdoi
Environmental Factors Associated With Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada - Genetic, Environmental, Microbial Project
Clinical Gastroenterology and Hepatology 2024cited by 28position: middledoi
GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN
Journal of Crohn s and Colitis 2024cited by 28position: middledoi
Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience
Inflammatory Bowel Diseases 2024cited by 20position: middledoi
Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN
Pediatric Drugs 2024cited by 14position: middledoi
STEP-CD study: ustekinumab use in paediatric Crohn’s disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN
European Journal of Pediatrics 2024cited by 10position: middledoi
Response to FDA draft guidance on pediatric IBD drug approval trials: A consensus statement from the IBD Porto Group
Journal of Pediatric Gastroenterology and Nutrition 2024cited by 7position: firstdoi
Enteral nutrition compared with corticosteroids in children with Crohn's disease: A long‐term nationwide study from the epi‐IIRN
Alimentary Pharmacology & Therapeutics 2024cited by 6position: lastdoi
Peripheral Blood Eosinophilia at Diagnosis of Inflammatory Bowel Disease Is Associated With Severe Disease Course: A Nationwide Study From the epi-IIRN Cohort
Journal of Crohn s and Colitis 2024cited by 4position: middledoi
The Pivotal ‘P’s of inflammatory bowel disease: Prediction and Prevention
United European Gastroenterology Journal 2024cited by 4position: lastdoi
Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN
Inflammatory Bowel Diseases 2023cited by 39position: middledoi
Durability of the First Biologic in Patients with Crohn’s Disease: A Nationwide Study from the epi-IIRN
Journal of Crohn s and Colitis 2023cited by 13position: lastdoi
Multi-item Measures for Paediatric Inflammatory Bowel Diseases: The ABCs of All Those Acronyms
Journal of Crohn s and Colitis 2023cited by 8position: lastdoi
Residence in Peripheral Regions and Low Socioeconomic Status Are Associated With Worse Outcomes of Inflammatory Bowel Diseases: A Nationwide Study From the epi-IIRN
Inflammatory Bowel Diseases 2023cited by 7position: lastdoi
Thiopurines Have Longer Treatment Durability than Methotrexate in Adults and Children with Crohn’s Disease: A Nationwide Analysis from the epi-IIRN Cohort
Journal of Crohn s and Colitis 2023cited by 7position: lastdoi
Thiopurines Maintenance Therapy in Children With Ulcerative Colitis: A Multicenter Retrospective Study
Journal of Pediatric Gastroenterology and Nutrition 2023cited by 4position: middledoi
Association of Antibiotic Use with Durability of Biologic Agents in Inflammatory Bowel Disease: a Report from the epi-IIRN
Journal of Crohn s and Colitis 2023cited by 3position: lastdoi
Gadolinium-Free Crohn’s Disease Assessment from Magnetic Resonance Enterography Data
2022 IEEE 19th International Symposium on Biomedical Imaging (ISBI) 2022cited by 2position: middledoi
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
Gastroenterology 2019cited by 58position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Iris Dotan · Tel Aviv University7 papers (2023–2024)Eran Matz · Atrium Health Wake Forest Baptist7 papers (2023–2024)Yiska Loewenberg-Weisband · Hebrew University of Jerusalem7 papers (2023–2024)Gili Focht · Hebrew University of Jerusalem6 papers (2022–2025) · 6 papers (2023–2024) · 6 papers (2023–2025)Oren Ledder · Hebrew University of Jerusalem6 papers (2023–2025)Dror S. Shouval · Tel Aviv University5 papers (2023–2025)Rona Lujan · Hebrew University of Jerusalem5 papers (2023–2024)Revital Kariv · Hebrew University of Jerusalem4 papers (2023–2024)Dotan Yogev · Hebrew University of Jerusalem4 papers (2023–2025)Séamus Hussey · Royal College of Surgeons in Ireland4 papers (2024–2025)C Friss · Hebrew University of Jerusalem4 papers (2023–2023) · 4 papers (2023–2024)Richard K. Russell · Centre for Inflammation Research4 papers (2024–2025)Lissy de Ridder · Erasmus MC - Sophia Children’s Hospital4 papers (2023–2025)Javier Martín de Carpi · Hospital Sant Joan de Déu Barcelona3 papers (2024–2025) · 3 papers (2023–2024)Amir Ben‐Tov · Université de Tours3 papers (2023–2024)Amit Assa · Hebrew University of Jerusalem3 papers (2024–2025)